

# Cytotoxicity Studies to Characterize Self-Assembling Amphiphiles for Targeted Cancer Drug Delivery


Anne E. Kim, Se Hye Kim, Samantha King, Aileen Shieh, and Jon R. Parquette\*  
OSU College of Arts and Sciences, Department of Chemistry



## Background


### Advantages of nanodrugs in anticancer research

- Improves water solubility and drug stability
- Prolongs circulation time
- Increased target specificity
- Facilitates passive accumulation in tumors via enhanced permeation and retention effect




### Camptothecin (CPT)

- Possesses potent antitumor properties that derive from its inhibition of topoisomerase I
- Showed remarkable anticancer activity in preliminary clinical trials
- Drawbacks: poor solubility under physiological conditions and unstable E-lactone ring



### Self-Assembly of CPT-peptide conjugates


- Peptide conjugation to CPT increases stability of drug
  - Preliminary data testing stability shows hydrolysis occurs at ester bond, not at lactone
- Hydrophilic portion (peptide) and hydrophobic portion (CPT) spontaneously assemble into nanotubes
- Once inside tumor cells, esterases will cleave ester bond → CPT will open to toxic form
- We have developed mono-, di-, and tetra-peptide conjugates




## Analysis of Drug

### Compound


- Compound of interest is  $\text{NH}_2\text{-K(CPT)-NH}_2$
- Monopeptide derivative is appealing due to simplicity, as opposed to di- and tetra-peptide
- Amide derivative is most favorable due to increased solubility, as opposed to methyl ester and free acid derivatives



### Imaging




Nanotube formation – 250  $\mu\text{M}$  in Phosphate Buffered Saline (PBS), was diluted from 10 mM stock solution (5.75  $\mu\text{g}$  of drug in 1.0 mL of PBS) that was stored at 4  $^\circ\text{C}$  for 1-month, aged for 3-days 23  $^\circ\text{C}$




Nanotube formation – 1 mM in PBS, was diluted from 10 mM stock solution (5.75  $\mu\text{g}$  of drug in 1.0 mL of PBS) that was stored at 4  $^\circ\text{C}$  for 1-month, aged for 3-days 23  $^\circ\text{C}$

## Analysis of Drug

### Cytotoxicity Tests



- Cytotoxicity tests were conducted to determine half maximal inhibitory concentration ( $\text{IC}_{50}$ ) levels to test efficacy of drug
- 3 non-small cell lung cancer cell lines (A549, H460, H23) with varying BCRP expression were used
- Drug was administered at varying concentrations and incubated with cells for 96 h
- Concentrations were diluted with PBS from 10 mM stock solution (5.75  $\mu\text{g}$  of drug in 1.0 mL of PBS) that was aged at 23  $^\circ\text{C}$  for 3 days, stored at 4  $^\circ\text{C}$  in between trials
- Preliminary data




- $\text{IC}_{50}$  levels of  $\text{NH}_2\text{-K}$  were compared with CPT, CPT-11 (clinically approved),  $\text{NH}_2\text{-KK}$ , and Ac-KK
- $\text{NH}_2\text{-K}$  appeared to be comparable to Ac-KK and less effective than  $\text{NH}_2\text{-KK}$

## Conclusions

- $\text{NH}_2\text{-K(CPT)-NH}_2$  shows promise based on collected data (TEM and cytotoxicity) so far
- There is formation of nanotubes due to amphiphilicity of molecule
- Cytotoxicity studies
  - Seemed to have similar effectiveness as Ac-KK, but is less effective than  $\text{NH}_2\text{-KK}$
  - Still more effective than CPT-11 (clinically approved drug)

## Future Steps



- Run E-lactone stability tests at pH 7.4 using high performance liquid chromatography
- Run more cytotoxicity trials to confirm preliminary data
- Quantitate accumulation of drug *in vitro* via flow cytometry
- Examine drug flow in cells with confocal images
- Determine biodistribution *in vivo*

## Acknowledgments

- Parquette group; Department of Chemistry and Biochemistry
- Croce group; Department of Molecular Virology, Immunology, and Medical Genetics
- Prof. Mark Grinstaff, Boston University